<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002164</url>
  </required_header>
  <id_info>
    <org_study_id>259E</org_study_id>
    <secondary_id>AG 1343-524</secondary_id>
    <nct_id>NCT00002164</nct_id>
  </id_info>
  <brief_title>Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants</brief_title>
  <official_title>Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agouron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the single dose pharmacokinetic profile of Viracept pediatric powder formulation&#xD;
      administered to HIV infected or exposed children and infants (0 to 13 years of age). An&#xD;
      evaluation of the relative bioavailability of the pediatric powder formulation vs. a standard&#xD;
      tablet formulation in older children (7 to 13 years of age) will also be conducted.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study of the safety, tolerability and pharmacokinetics of a Viracept pediatric&#xD;
      powder formulation with milk or formula. First a single dose will be administered. After the&#xD;
      patient population is divided into 4 groups by age, an optimal dose will be determined for&#xD;
      each group. This optimal dose will be given 3 times a day for a 6 week primary observation&#xD;
      period, plus an optional 6 month extension.&#xD;
&#xD;
      NOTE: During the single dose portion of this study, patients may be untreated or may continue&#xD;
      treatment with their current nucleoside antiretroviral therapy. During multiple dose&#xD;
      administration of Viracept, antiretroviral therapy will be intensified by either adding or&#xD;
      modifying therapy. Antiretroviral therapies will be limited to those currently licensed&#xD;
      including zidovudine, lamivudine, stavudine, didanosine or zalcitabine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>24</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelfinavir mesylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
        Administration of Pneumocystis carinii pneumonia prophylaxis according to CDC guidelines&#xD;
        will be permitted.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  For children &gt;= 3 months to 13 years of age:&#xD;
&#xD;
          -  HIV infection. For children &lt;3 months of age:&#xD;
&#xD;
          -  HIV infection or exposure.&#xD;
&#xD;
          -  Newborns must have birth weight &gt;= 2500 gm.&#xD;
&#xD;
          -  Absence at screen of any serious or unstable medical conditions.&#xD;
&#xD;
          -  Parent or guardian able to give written informed consent and willing to comply with&#xD;
             study requirements.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with any of the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Children with HIV associated malignancy requiring chemotherapy.&#xD;
&#xD;
          -  Children with clinical or laboratory assessments greater than Grade 1 in the Toxicity&#xD;
             Table at the time of the screening.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Chemotherapy.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Protease inhibitors.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Patients who have taken investigational agents, immunomodulators, HIV-1 vaccines,&#xD;
             glucocorticoids or unconventional therapies within one month prior to the day 0 of the&#xD;
             study must be evaluated to determine the impact of these treatments on the study.&#xD;
             Patients may be included or excluded on a case to case basis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Day</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA School of Medicine / Dept of Pediatrics</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 1999</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Biological Availability</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>Dosage Forms</keyword>
  <keyword>Nelfinavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nelfinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

